北京天智航医疗科技股份有限公司 关于 2023 年限制性股票激励计划首次及预留授予部分 北京天智航医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 和《北京天智航医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，对本次限制性股票激励计划首次及预留授予部分第二个归属期符合归属 条件的激励对象名单进行审核，发表核查意见如下： 经核查，除 11 名激励对象（首次授予 5 名，预留授予 9 名，首次和预留人 员存在重合）离职外，本激励计划首次及预留授予拟归属的 148 名激励对象（首 次授予 95 名，预留授予 117 名，首次和预留人员存在重合）绩效考核结果合规、 真实，不存在虚假、故意隐瞒等相关情况，符合《公司法》《证券法》等法律、 法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市 规则》等法律、法规和规范性文件规定的激励对象条件，符合《公司 ...

证券代码：688277 证券简称：天智航 公告编号：2025-035 北京天智航医疗科技股份有限公司 关于增加 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否需要提交股东大会审议：是 ? 日常关联交易对公司的影响：本次增加 2025 年度日常关联交易预计额度 事项属于公司日常关联交易，是以公司正常生产经营业务为基础，以市场价格为 定价依据，不影响公司的独立性，不存在损害公司及股东利益的情形，不会对关 联人形成较大的依赖。 一、增加日常关联交易基本情况 （一）增加日常关联交易履行的审议程序 召开第六届董事会独立董事专门会议第六次会议审议通过了《关于增加 2025 年 度日常关联交易预计额度的议案》，该议案获得全体独立董事一致同意，并同意 将该议案提交公司董事会审议。 会第十次会议，分别审议通过了《关于增加 2025 年度日常关联交易预计额度的 议案》，本次增加 2025 年度日常关联交易预计额度为 3,000.00 万元，关联董事 张送根、王彬彬进行了回避表 ...

Core Viewpoint - The report outlines Beijing Tianzhihang Medical Technology Co., Ltd.'s progress and effectiveness in implementing its "Quality Improvement and Efficiency Enhancement" action plan for 2025, emphasizing its commitment to high-quality development and innovation in the orthopedic surgery robot industry. Group 1: Business Performance - The company achieved a revenue of 125.31 million yuan, representing a year-on-year growth of 114.89% [2] - The Tianji orthopedic surgical robot performed over 22,000 surgeries from January to June 2025, with a cumulative total exceeding 120,000 surgeries by the end of the reporting period [2] - The company is focused on enhancing product performance and expanding its product range, covering various orthopedic surgical procedures [2] Group 2: Research and Innovation - The company has applied for a total of 619 patents, including 245 invention patents, and has been granted 428 patents, with 412 currently valid [3] - Two innovative products, Tianji SIRUI orthopedic surgical robot and Tianxuan Xingyao 3D C-arm, received approval for market launch, enhancing surgical efficiency and safety [3] Group 3: Corporate Governance - The company has established a robust governance structure, ensuring clear responsibilities and effective checks and balances [4] - Training programs have been implemented to enhance compliance awareness among major stakeholders [4] Group 4: Talent Development - The company emphasizes talent development through comprehensive training programs tailored to various employee needs [5] - Long-term incentive mechanisms have been established to attract and retain top talent, aligning interests among shareholders, the company, and core team members [5] Group 5: Information Disclosure - The company prioritizes information disclosure to enhance governance and market transparency, adhering to relevant regulations [6] - Various initiatives have been undertaken to communicate with investors, including performance briefings and investor engagement activities [6]

Core Viewpoint - The report confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. has met the vesting conditions, allowing for the allocation of shares to eligible participants [6][10][16]. Summary by Sections Definitions - The report defines key terms related to the incentive plan, including "restricted stock," "incentive objects," and "vesting conditions," which are essential for understanding the plan's framework [1][2]. Approval Process - The 2023 restricted stock incentive plan has undergone necessary approval procedures, including resolutions from the board of directors and the supervisory board, confirming the plan's compliance with relevant regulations [4][6]. Vesting Conditions Achievement - The board of directors has reviewed and confirmed that the vesting conditions for the second vesting period have been met, allowing for the allocation of 3.86466 million shares to 148 eligible participants [6][10]. Performance Requirements - The performance requirements for the incentive plan include achieving a revenue growth rate of at least 40% for the first vesting period and 90% for the second vesting period, or obtaining medical device registration for at least two new orthopedic surgical robots [10][11]. Allocation Details - For the first grant, 95 participants are eligible to receive 3.135355 million shares, while for the reserved grant, 117 participants are eligible for 729305 shares, both at a grant price of 8.66 yuan per share [12][14][15]. Independent Financial Advisor's Opinion - The independent financial advisor concludes that the vesting conditions have been met and that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [16].

Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. meets the vesting conditions and outlines the circumstances under which certain restricted stocks will be canceled [2][5][21]. Group 1: Approval and Authorization - The company has completed necessary procedures for the implementation of the 2023 restricted stock incentive plan, including approval from the board and supervisory committee [6][7]. - The independent directors have expressed that the implementation of the incentive plan is beneficial for the company's governance structure and does not harm the interests of shareholders, especially minority shareholders [7][8]. Group 2: Vesting Conditions - The second vesting period for the initial grant of restricted stocks began on May 12, 2023, and the pre-allocated grant's second vesting period will start on August 22, 2025 [10][11]. - The company has confirmed that the vesting conditions have been met, including the absence of negative audit opinions and compliance with legal regulations [11][14]. Group 3: Specifics of the Vesting - The initial grant date was May 12, 2023, with 95 individuals eligible for a total of 3.135355 million shares at a grant price of 8.66 yuan per share [20]. - The pre-allocated grant date is August 22, 2023, with 117 individuals eligible for a total of 0.729305 million shares at the same grant price [20]. Group 4: Cancellation of Restricted Stocks - A total of 172,095 restricted stocks will be canceled due to the departure of individuals who no longer meet the eligibility criteria [22]. - The cancellation aligns with the regulations set forth in the management measures and listing rules [21][22]. Group 5: Conclusion - The legal opinion concludes that both the vesting and cancellation of restricted stocks have received the necessary approvals and comply with relevant regulations [22][23].

中信建投证券股份有限公司 关于北京天智航医疗科技股份有限公司 增加 2025 年度日常关联交易预计额度的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为北京天智航医疗科技股份有限公司（以下简称"天智航"或"公司"）2021 年度向特定对象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理 办法》 《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》和《科创板上市公司持续监管办法（试行）》 等有关规定，对天智航增加 2025 年度日常关联交易预计额度事项进行了审慎核 查，核查情况及核查意见如下： 一、增加日常关联交易基本情况 （一）增加日常关联交易履行的审议程序 审议通过了《关于增加 2025 年度日常关联交易预计额度的议案》，该议案获得全 体独立董事一致同意，并同意将该议案提交公司董事会审议。 会第十次会议，分别审议通过了《关于增加 2025 年度日常关联交易预计额度的 议案》，本次增加 2025 年度日常关联交易预计额度为 3,000.00 万元，关联董事张 送根、王彬彬进行了回避表决。 本次日常关联交易预计事项 ...

证券代码：688277 证券简称：天智航 公告编号：2025-034 北京天智航医疗科技股份有限公司 关于作废 2023 年限制性股票激励计划部分已授予尚未归属 的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第六届董事会第二十二次会议、第五届监事会第十次会议，审议通过了 《关于作废 2023 年限制性股票激励计划部分已授予尚未归属的限制性股票的议 案》。现将有关事项说明如下： 一、本激励计划已履行的相关审批程序 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 大会授权董事会办理公司 2023 年限制性股票激励计划有关事项的议案》等相关 议案。公司独立董事就本次激励计划相关议案发表了独立意见。 的信息在公司内部进行了公示。截至公示期满，公司监事会未收到任何人对本次 拟 激 励 对 象 提 出 的 异 议 。 ...

Core Points - The company announced that the second vesting period of the 2023 restricted stock incentive plan has met the vesting conditions, allowing for the vesting of 3.86466 million shares, which accounts for 0.85% of the company's total share capital [1][10][18] Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan is not to exceed 8.6875 million shares, with the initial grant accounting for 6.878 million shares (1.53% of total share capital) and the reserved grant accounting for 1.7195 million shares (0.38% of total share capital) [1][2] - The vesting schedule includes two periods: the first vesting period is 24 months after the initial grant, and the second vesting period is 36 months after the initial grant [2][10] Group 2: Performance Assessment Criteria - The performance assessment for the initial grant includes two conditions: a revenue growth rate of at least 90% in 2024 compared to 2022, or obtaining at least two new orthopedic surgical robots' medical device registration licenses during 2023-2024 [3][4] - For the reserved grant, the performance assessment criteria are similar but adjusted for the years 2024-2025, requiring a revenue growth rate of at least 140% in 2025 compared to 2022, or obtaining at least three new orthopedic surgical robots' medical device registration licenses during 2023-2025 [4][5] Group 3: Approval and Compliance - The incentive plan has undergone necessary approvals, including independent opinions from the board and the supervisory committee, confirming compliance with relevant regulations [6][15] - The supervisory committee verified the eligibility of 148 incentive recipients, with 95 from the initial grant and 117 from the reserved grant, confirming that the performance assessment results are compliant and truthful [18][20]

2025 年上半年，公司优化产品结构，不断完善产品体系建设，持续推进产 品向高性价比、高性能迭代升级，不断丰富产品种类和产品功能。目前，公司产 品适应证已实现覆盖全节段脊柱外科手术、骨科创伤手术、全膝关节置换手术、 全髋关节置换手术。 2025 年上半年，公司积极通过参与行业展会、学术论坛及活动等方式，加 强公司产品骨科手术机器人技术及品牌推广，进一步增强下游客户对公司品牌的 认同与粘性，为后续深化业务合作，加快开拓市场份额。 北京天智航医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 北京天智航医疗科技股份有限公司（以下简称"公司"或"天智航"）为切 实践行"以投资者为本"的上市公司发展理念，维护公司全体股东特别是广大中 小投资者利益，基于对公司未来发展前景的信心、对公司价值的认可和切实履行 社会责任，于 2025 年 4 月 29 日发布《关于 2024 年度"提质增效重回报"行动 方案的年度评估报告暨 2025 年度"提质增效重回报"行动方案》，为公司 2025 年度提质增效重回报行动制定出明确的工作方向。公司根据行动方案内容，积极 开展和落实各项工作，现将 2025 ...

1、首次公开发行股票 根据中国证券监督管理委员会于 2020 年 5 月 26 日出具的《关于同意北京天 智航医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕 1001 号），公司首次向社会公众公开发行人民币普通股（A 股）4,190.00 万股， 每股面值为人民币 1.00 元，每股发行价格为人民币 12.04 元，募集资金总额合计 为人民币 504,476,000.00 元，扣除承销及保荐费用、发行登记费以及其他交易费 用共计人民币 56,175,293.91 元（不含增值税进项税）后，本次募集资金净额为 人民币 448,300,706.09 元。上述资金已于 2020 年 6 月 30 日全部到位，经上会会 计师事务所（特殊普通合伙）审验并出具上会师报字[2020]第 5707 号《验资报 告》。募集资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账 户内，公司与保荐机构、存放募集资金的商业银行签署了《募集资金专户存储三 方监管协议》。 证券代码：688277 证券简称：天智航 公告编号：2025-032 北京天智航医疗科技股份有限公司 2025 年半年度募集资金存放与使 ...